Navigation Links
CHMP Adopts Negative Opinion for ZEFTERA(TM)
Date:2/19/2010

BEERSE, Belgium, February 19, 2010 /PRNewswire-FirstCall/ --

- Cilag GmbH International to Terminate Collaboration

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections.

Cilag GmbH International has given Basilea Pharmaceutica Ltd. notice of termination of the worldwide License , Development and Co-Promotion Agreement between the parties. The compound, including pending applications and in-market products, will be transitioned back to Basilea under the terms of the License Agreement.

Janssen-Cilag International NV and Cilag GmbH International are Johnson & Johnson companies.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Janssen-Cilag International NV and Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Neither Janssen-Cilag International NV nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

For further information, please contact: Media: Karen Manson - Office: +44-1737-644-690or Investor Relations: Stan Panasewicz - Office: +1-732-524-2524

SOURCE Janssen-Cilag International NV

Back to top
'/>"/>
SOURCE Janssen-Cilag International NV
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech, Inc. Adopts Stockholder Rights Plan
2. The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management
3. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
4. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
5. SAFC Adopts Targeted Approach to Reach Pre-Registration
6. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
7. Gowlings Adopts RFID and Unifies Practice Management
8. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
9. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
10. Informed Medical Communications Adopts Newly Enhanced Compliance Policy
11. Atom Medical Adopts Masimo Rainbow SET Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):